Analyst Profile

Followed by 249 followers
.
Andrew Berens

Andrew Berens

SVB Securities
Wall Street Analyst
#2,101 out of 8,112 Wall Street Analysts
#4,513 out of 24,193 experts

Success Rate

45%
184 out of 405 transactions made a profit

Average Return

+3.20%
Average return per transaction
Time Frame
1 Year
Compare to
No Benchmark
Copying Andrew Berens's trades since 2014 and holding each position for 1 Year would result in 45.43% of your transactions generating a profit, with an average return of 3.2% per rating.

Stock Rating Distribution

617Ratings
73.10% Buy
17.67% Hold
9.24% Sell
Distribution of Andrew Berens's ratings

Additional Information

Main Sector:Healthcare
Geo Coverage:
United StatesUS Market

Best Rating

Stock:
AVEO Pharmaceuticals
(AVEO)
Rating:Buy
Date:Feb 08, 2022 - Oct 24, 2022
Return:+322.90%
The most profitable rating made by Andrew Berens

Andrew Berens's Stock Coverage

Company
Date
Position
Action
Price Target
No. of Ratings
Success Rate
Avg. Return
NPSP
NPS Pharma
Sep 10, 2014
Buy
Reiterated
2Ratings
100%
+43.30%
~ACHN
Achillion Pharmaceuticals
Dec 01, 2014
Hold
Reiterated
5Ratings
100%
+26.00%
Gilead Sciences
Dec 01, 2014
Hold
Reiterated
3Ratings
0.00%
AMAG
Amag Pharmaceuticals
Dec 01, 2014
Hold
Reiterated
3Ratings
0.00%
Enanta Pharmaceuticals
Dec 01, 2014
Hold
Reiterated
2Ratings
0.00%
ZSPH
ZS Pharma
Nov 09, 2015
Hold
Downgraded
4Ratings
100%
+35.30%
Carlyle Group
Feb 17, 2016
Buy
Upgraded
$20.00
(-31.93% Downside)
1Ratings
100%
+24.30%
KERX
Keryx Biopharma
Jul 18, 2016
Hold
Reiterated
9Ratings
100%
+64.67%
Akebia Therapeutics
Jul 18, 2016
Buy
Reiterated
5Ratings
75%
+34.40%
Rockwell Med
Jul 18, 2016
Sell
Reiterated
6Ratings
100%
+20.08%
List of latest recommendations made by Andrew Berens. Click to expand and see Andrew Berens's performance on a particular stock
Disclaimer: TipRanks collects analysts’ ratings and price targets by scanning publicly available reports on financial websites and by receiving reports from analysts, firms, or customers. The information and statistics displayed might not be accurate, complete, or up-to-date. The analyst ratings provided are the sole responsibility of the source publication. TipRanks holds no liability over the analysts' information, price targets, ratings, or opinions expressed.
Send Us Reports
If you receive reports that you think we are missing, we will thank you with a free Ultimate upgrade!
Learn More >